The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Infections following anti-BCMA bispecific antibodies for multiple myeloma
Ajai Chari, MD, PhD, Mount Sinai School of Medicine, New York City, NY, discusses findings from a recent study investigating the occurrence and kinetics of infections following treatment with anti-BCMA bispecific antibodies in patients with multiple myeloma. The study reported a high rate of grade 3-5 infections that continued to increase with time. However, Dr Chari highlights that intravenous immunoglobulin (IVIg) administration can be a very effective prophylactic strategy to reduce the risk of infections. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Paid Consultant for Janssen
